FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product

Summary

The FDA has awarded a priority review voucher to Spark Therapeutics, Inc., the manufacturer of LUXTURNA, a rare pediatric disease product, following a review of the product's eligibility under the FD&C Act and FDASIA.